Shanghai ZJ Bio-Tech Corp., Ltd., as known as Liferiver, is a leading molecular diagnostics company, with advanced technology and complete line of products, fully engaged in the research, development, production and sale of diagnostic reagents and instruments, focusing on supply of molecular diagnostic solutions for clinical application and scientific research.
With molecular diagnostic reagents and instruments as the main business, Liferiver is one of the few companies in China with comprehensive line of molecular diagnostic products for infectious diseases, has developed more than 400 kinds of assays, which cover most national notifiable diseases and are widely used in public health emergency, clinical diagnosis, border inspection, food safety and other fields.
Liferiver upholds the principle of "Quality First, Service First", and is building a world-class molecular diagnostics brand. Liferiver has always been at the forefront of research & development for epidemic prevention & control, and has made indelible contributions in public health emergencies, ranging from H1N1 to H7N9, Ebola, Zika and COVID-19.
Liferiver has undertaken 20 plus key national and provincial scientific research projects, won more than 10 major awards such as the second prize of Shanghai Science and Technology Award. A number of products have been approved by WHO.
| Full name | Shanghai ZJ Bio-Tech Co., Ltd. |
|---|---|
| Abbreviations | LIFERIVER |
| Code | 688317 |
| Founded | 2005-04-18 |
| Listing | 2021-01-18 |
| Domicile | Shanghai, China |
| Website | www.liferiver.com.cn |
| info@liferiver.com.cn | |
| STAR Theme | Biomedicine |
| CSRC Sector | Biomedicine Manufacturing (C27) |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 6.38 | 0.35 | 0.43 |
| R&D expenditure as a % of operating revenue | 2.55% | 9.04% | 8.88% |
| Operating Revenue | 2,052.14 | 258.87 | 224.35 |
| Net Income | 932.01 | 51.52 | 62.32 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 2,052.14 | 258.87 | 224.35 |
| Operating Costs | 939.61 | 203.34 | 160.57 |
| Operating Income | 1,111.66 | 61.31 | 72.61 |
| Pretax Income | 1,109.20 | 61.03 | 72.46 |
| Income Tax | 177,19 | 9.51 | 10.14 |
| Net Income | 932.01 | 51.52 | 62.32 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 1,582.92 | 403.67 | 405.15 |
| Non-current Assets-Total | 296.66 | 238.26 | 174.48 |
| Total Assets | 1,879.57 | 641.93 | 579.64 |
| Liabilities | |||
| Current Liabilities-Total | 385.39 | 56.97 | 42.24 |
| Non-current Liabilities-Total | 31.58 | 13.12 | 4.73 |
| Total Liabilities | 416.97 | 70.09 | 46.98 |
| Stockholder's Equity | |||
| Share Capital | 402.57 | 402.57 | 402.57 |
| Retained Profits | 1,060.03 | 169.27 | 130.09 |
| Total Owners' Equity | 1,462.60 | 571.84 | 532.66 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 1,141.80 | 76.66 | 80.63 |
| Net Cash Flows-Investing | -86.30 | -31.56 | -24.48 |
| Net Cash Flows-Financing | -68.50 | -65.71 | -0.19 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 上海之江药业有限公司 | 64.97 | 44.49% |
| Lucent (Shanghai) Investment Center (L.P.) | 39.45 | 27.02% |
| 宁波睿道创业投资合伙企业（有限合伙） | 10.81 | 7.41% |
| Shanghai Nengfa Investment Consulting Co., Ltd. | 7.64 | 5.23% |
| Ningbo Kangfeidunsi Investment Management Partnership(L.P.) | 6.00 | 4.11% |
| Ningbo Jinghui Maizuo Venture Capital Partnership (L.P.) | 2.54 | 1.74% |
| 上海高特佳懿海投资合伙企业（有限合伙） | 2.14 | 1.46% |
| Hangzhou Tengchang Investment Management Partnership (L.P.) | 2.09 | 1.43% |
| Shanghai Maijing Nano Technology Co., Ltd. | 1.65 | 1.13% |
| Orient Securities Limited | 1.45 | 0.99% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.